-Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately$75 million by Q2 2025- -Strong sequential 39% Q/Q growth on Point-of-Care revenues associated with successful rollout and scaling of HIV test production- -Disciplined execution of operational efficiencies led to 3.6 percentage point Q/Q increase in gross margin percentage with further improvements expected through 2024 and into early 2025- DUBLIN, Ireland, May 23, 202 ...